← Back to guidelines
Dermatology103 papers

Drug-induced androgenic alopecia

Last edited: 4/15/2026

Overview

Drug-induced androgenic alopecia refers to hair loss conditions exacerbated or caused by medications that affect androgen levels or sensitivity, notably finasteride used for treating androgenic alopecia and benign prostatic hyperplasia 1.

Diagnosis

  • Physical examination focusing on hair changes and other signs of androgen excess 2.
  • Laboratory tests to assess androgen levels and receptor sensitivity 2.
  • Consideration of patient history for medication use, particularly finasteride 1.
  • Management

  • First-line treatments:
  • - For elevated androgen levels: Oral contraceptives for ovarian suppression 2. - For adrenal androgen excess: Glucocorticoids to suppress adrenal activity 2.
  • Adjunctive therapies: Medications targeting androgen receptor blockade, though specific drugs and doses not detailed in provided abstracts 2.
  • Special Populations

  • Pregnancy: No specific guidance provided in abstracts 2.
  • Pediatrics: Not addressed in provided abstracts 2.
  • Elderly: Increased vigilance for cognitive dysfunction in elderly patients, especially those with alopecia treated with finasteride 1.
  • Comorbidities: Management should consider underlying endocrine causes alongside comorbidities, with a focus on slow response times to therapy 2.
  • Key Recommendations

  • Monitor elderly patients, particularly those with alopecia, for cognitive dysfunction when using finasteride (Evidence: Moderate 1).
  • Employ oral contraceptives for ovarian suppression in women with elevated androgen levels contributing to androgenic alopecia (Evidence: Moderate 2).
  • Consider glucocorticoid therapy for adrenal androgen suppression in appropriate cases (Evidence: Moderate 2).
  • References

    1 Cho Y, Bea S, Bae JH, Kim DH, Lee JH, Shin JY. Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database. Expert opinion on drug safety 2024. link 2 Redmond GP. Androgenic disorders of women: diagnostic and therapeutic decision making. The American journal of medicine 1995. link80070-9)

    Original source

    1. [1]
      Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database.Cho Y, Bea S, Bae JH, Kim DH, Lee JH, Shin JY Expert opinion on drug safety (2024)
    2. [2]
      Androgenic disorders of women: diagnostic and therapeutic decision making.Redmond GP The American journal of medicine (1995)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG